The Applications of Focused Ultrasound (FUS) in Alzheimer’s Disease Treatment: A Systematic Review on Both Animal and Human Studies
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) affects the basic ability to function and has imposed an immense burden on the community and health care system. Focused ultrasound (FUS) has recently been proposed as a novel noninvasive therapeutic approach for AD. However, systematic reviews on the FUS application in AD treatment have not been forthcoming. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria to summarize the techniques associated with safety and efficacy, as well as possible underlying mechanisms of FUS effects on AD in animal and human studies. Animal studies demonstrated FUS with microbubbles (FUS-MB) induced blood-brain-barrier (BBB) opening that could facilitate various therapeutic agents entering the brain. Repeated FUS-MB and FUS stimulation can relieve AD pathology and improve cognitive and memory function. Human studies showed repeated FUS-MB are well tolerated with few adverse events and FUS stimulation could enhance local perfusion and neural function, which correlated with cognitive improvement. We conclude that FUS is a feasible and safe therapeutic and drug delivery strategy for AD. However, FUS treatment on humans is still in the early stages and requires further optimization and standardization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SYRCLE’s risk of bias tool for animal studies
Hooijmans, C. R., Rovers, M. M., de Vries, R. B., Leenaars, M., Ritskes-Hoitinga, M., & Langendam, M. W. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-43 · Cited by 4,415 · cited 1×
“The Systematic Review Center for Laboratory Animal Experimentation risk of bias (SYRCLE’s RoB) tool [30] was used to assess risk of bias in the animal studies.”
MethodBlood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076
Oxidative stress and the amyloid beta peptide in Alzheimer’s disease
Cheignon, C., Tomas, M., Bonnefont-Rousselot, D., Faller, P., Hureau, C., & Collin, F. (2018) · Redox Biology · doi:10.1016/j.redox.2017.10.014 · Cited by 2,185 · cited 1×
“The production of reactive oxygen species (ROS) is catalyzed by redox active metal ions bound to Aβ [56].”
BackgroundBlood-brain barrier breakdown in the aging human hippocampus
Montagne, A., Barnes, S. R., Sweeney, M. D., Halliday, M. R., Sagare, A. P., Zhao, Z., Toga, A. W., Jacobs, R. E., Liu, C. Y., Amezcua, L., et al. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.032 · Cited by 2,102
The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., et al. (2018) · Brain · doi:10.1093/brain/awy132 · Cited by 1,918
Establishment and Dysfunction of the Blood-Brain Barrier
Zhao, Z., Nelson, A. R., Betsholtz, C., & Zlokovic, B. V. (2015) · Cell · doi:10.1016/j.cell.2015.10.067 · Cited by 1,670 · cited 1×
“, P-glycoprotein (Pgp)) and ion transporters allow the exchanges of energy metabolites, nutrients, regulatory molecules and metabolic waste products [75].”
BackgroundClinimetrics: Physiotherapy Evidence Database (PEDro) Scale
Cashin, A. G., & McAuley, J. H. (2020) · Journal of Physiotherapy · doi:10.1016/j.jphys.2019.08.005 · Cited by 975
Blood-brain barrier opening in Alzheimer’s disease using MR-guided focused ultrasound
Lipsman, N., Meng, Y., Bethune, A. J., Huang, Y., Lam, B., Masellis, M., Herrmann, N., Heyn, C., Aubert, I., Boutet, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04529-6 · Cited by 950
Alzheimer’s disease: A matter of blood–brain barrier dysfunction?
Montagne, A., Zhao, Z., & Zlokovic, B. V. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20171406 · Cited by 672 · cited 1×
“Numerous animal and postmortem human studies have confirmed BBB breakdown takes place in the AD brain, which exhibits extravascular leakage, pericyte and endothelial degeneration, as well as loss of BBB tight junctions [65, 66].”
BackgroundThe Glymphatic System and Waste Clearance with Brain Aging: A Review
Benveniste, H., Liu, X., Koundal, S., Sanggaard, S., Lee, H., & Wardlaw, J. (2019) · Gerontology · doi:10.1159/000490349 · Cited by 517 · cited 1×
“and are drained to deep cervical lymph nodes (dCLN) [62].”
BackgroundSelf-citationScanning ultrasound removes amyloid-β and restores memory in an Alzheimer’s disease mouse model
Leinenga, G., & Götz, J. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa2512 · Cited by 498 · cited 2×
“Activated astrocytes and microglia internalize Aβ and contribute to plaque reduction [15, 16, 34].”
BackgroundGSK-3β, a pivotal kinase in Alzheimer disease
Llorens-MarÃtin, M., Jurado, J., Hernández, F., & Ãvila, J. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00046 · Cited by 451
Noninvasive hippocampal blood-brain barrier opening in Alzheimer's disease with focused ultrasound.
Rezai, A. R., Ranjan, M., D’Haese, P.-F., Haut, M. W., Carpenter, J., Najib, U., Mehta, R. I., Chazen, J. L., Zibly, Z., Yates, J. R., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2002571117 · Cited by 365 · cited 3×
“Rezai et al. (2020) Early AD patients (n=6) Type: MRIgFUS Frequency: 220kHz MB: Definity Three treatment sessions with 2 weeks interval Hippocampus and EC Enhancement appeared at the targeted site on Gadoliniumbasedcontrast MRI All patients tolerated well, no treatmentrelated adverse effects or…”
BackgroundJordão, J. F., Thévenot, E., Markham-Coultes, K., Scarcelli, T., Weng, Y.-Q., Xhima, K., O'Reilly, M., Huang, Y., McLaurin, J., Hynynen, K., et al. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.05.008 · Cited by 326 · cited 8×
“2013) used twice the dose of MB (Definity) for 4 months old TgCRND8 mice, suggesting an altered vascular response to FUS in TgCRND8 mice [15].”
BackgroundMethodInfluentialBurgess, A., Dubey, S., Yeung, S., Hough, O., Eterman, N., Aubert, I., & Hynynen, K. (2014) · Radiology · doi:10.1148/radiol.14140245 · Cited by 286 · cited 9×
“FUS-MB treatment reduced acetylcholinesterase (AChE) activity, increased Ach release and promoted BDNF expression in the hippocampus, which upregulated neuroplasticity and neurogenesis (increased DCX+ and BrdU+ cells) via Akt signaling, resulting in improvements in cognitive and memory function [16, 21].”
BackgroundMethodInfluentialBrain imaging of neurovascular dysfunction in Alzheimer’s disease
Montagne, A., Nation, D. A., Pa, J., Sweeney, M. D., Toga, A. W., & Zlokovic, B. V. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1570-0 · Cited by 239
Emerging roles of ER stress in the etiology and pathogenesis of Alzheimer's disease
Gerakis, Y., & Hetz, C. (2018) · The FEBS Journal · doi:10.1111/febs.14332 · Cited by 226
Nisbet, R. M., Van der Jeugd, A., Leinenga, G., Evans, H. T., Janowicz, P. W., & Götz, J. (2017) · Brain · doi:10.1093/brain/awx052 · Cited by 187 · cited 6×
“SUS equipped with a motorized positioning system can move the transducer in small increments to cover large anatomic regions and is often used for whole brain drug delivery [7, 33].”
BackgroundMethodInfluentialDeinhardt, K., & Chao, M. V. (2014) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-45106-5_5 · Cited by 147
Liu, Y., Gong, Y., Xie, W., Huang, A., Yuan, X., Zhou, H., Zhu, X., Chen, X., Liu, J., Liu, J., et al. (2020) · Nanoscale · doi:10.1039/c9nr09713a · Cited by 123
Glymphatics visualization after focused ultrasound-induced blood-brain barrier opening in humans
Meng, Y., Abrahao, A., Heyn, C. C., Bethune, A. J., Huang, Y., Pople, C. B., Aubert, I., Hamani, C., Zinman, L., Hynynen, K., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25604 · Cited by 114 · cited 4×
“[38] detected MRI hyperintensity within the perivascular space and subarachnoid space (SAS) on contrast enhanced fluidattenuated inversion recovery (FLAIR) imaging after FUS-MB treatment, suggesting glymphatic efflux persists following FUS-MB induced BBB opening.”
BackgroundResultInfluentialThe effects of cerebral amyloid angiopathy on integrity of the blood-brain barrier
Magaki, S., Tang, Z., Tung, S., Williams, C. K., Lo, D., Yong, W. H., Khanlou, N., & Vinters, H. V. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.06.004 · Cited by 93
Hsu, P.-H., Lin, Y.-T., Chung, Y.-H., Lin, K.-J., Yang, L.-Y., Yen, T.-C., & Liu, H.-L. (2018) · Scientific Reports · doi:10.1038/s41598-018-31071-8 · Cited by 70 · cited 4×
“anti-tau antibodies (29 kDa-156 kDa) and glycogen synthase kinase (GSK)3 (308 kDa)) and nanoparticles (Qc@SNPs), demonstrating excellent therapeutic effects [7, 9, 12].”
BackgroundInfluentialLeinenga, G., Koh, W. K., & Götz, J. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.08.002 · Cited by 31 · cited 2×
“…(4) Repeated LIPUS stimulations activate endothelial cells that may have effects on astrocytes, resulting in improvement of cognitive functions Leinenga et al. (2019) 12-14 months old APP23 mice (n=6) WT (n=5) Type: SUS Frequency: 1MHz Acoustic pressure: 0.7 MPa Burst length: 10ms…”
BackgroundInfluential
Cited by
Noel, R. L., Batts, A. J., Ji, R., Pouliopoulos, A. N., Bae, S., Kline-Schoder, A. R., & Konofagou, E. E. (2023) · Scientific Reports · doi:10.1038/s41598-023-30466-6 · Cited by 27
Natural Products from Plants and Algae for Treatment of Alzheimer’s Disease: A Review
Klose, J., Griehl, C., Roßner, S., & Schilling, S. (2022) · Biomolecules · doi:10.3390/biom12050694 · Cited by 23
Bai, M., Lyv, H., Zhou, X., Zhang, Y., & Han, Z. (2025) · Journal of Alzheimer's Disease Reports · doi:10.1177/25424823251343789 · Cited by 7
Metadata
- Authors
- Liu, X., Naomi, S. S. M., Sharon, W. L., & Russell, E. J.
- Venue
- Aging and disease
- Publisher
- Aging and Disease
- Published
- 2021
- Volume
- 12
- Issue
- 8
- Pages
- 1977
- ISSN
- 2152-5250 (ISSN-L)
- OpenAlex
- W4200136941
- Cited by
- 52
- References
- 24
- FWCI
- 0.89
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.